Compare ENVX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | OLMA |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2020 |
| Metric | ENVX | OLMA |
|---|---|---|
| Price | $4.97 | $15.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $13.61 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 5.1M | 1.7M |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $38.76 | N/A |
| Revenue Next Year | $218.24 | $347.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.67 | $2.86 |
| 52 Week High | $16.49 | $36.26 |
| Indicator | ENVX | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 39.79 |
| Support Level | $4.69 | $13.11 |
| Resistance Level | $5.56 | $27.38 |
| Average True Range (ATR) | 0.31 | 0.99 |
| MACD | 0.07 | 0.30 |
| Stochastic Oscillator | 31.58 | 58.89 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.